-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
New York State Common Retirement Fund Cuts Stock Position in Orchard Therapeutics Plc (NASDAQ:ORTX)
New York State Common Retirement Fund Cuts Stock Position in Orchard Therapeutics Plc (NASDAQ:ORTX)
New York State Common Retirement Fund lessened its position in Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) by 66.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 323,397 shares of the company's stock after selling 632,861 shares during the quarter. New York State Common Retirement Fund's holdings in Orchard Therapeutics were worth $230,000 at the end of the most recent reporting period.
Separately, SG Americas Securities LLC purchased a new stake in Orchard Therapeutics during the 4th quarter worth about $858,000. Institutional investors and hedge funds own 56.47% of the company's stock.
Get Orchard Therapeutics alerts:Analysts Set New Price Targets
Separately, Barclays cut their price target on Orchard Therapeutics from $6.00 to $4.00 in a report on Friday, May 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Orchard Therapeutics has an average rating of "Hold" and a consensus target price of $7.75.
Orchard Therapeutics Price Performance
Shares of NASDAQ ORTX opened at $0.56 on Monday. The stock's 50-day moving average is $0.59 and its two-hundred day moving average is $0.67. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.24 and a quick ratio of 4.24. Orchard Therapeutics plc has a 1-year low of $0.41 and a 1-year high of $3.18. The company has a market cap of $70.80 million, a price-to-earnings ratio of -0.42 and a beta of 0.80.Orchard Therapeutics Company Profile
(Get Rating)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.
Further Reading
- Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Near-Term Headwinds Present An Opportunity In Ross Stores
- Apple's Stock Could Be On The Verge Of Another 30% Rally
Want to see what other hedge funds are holding ORTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating).
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
New York State Common Retirement Fund lessened its position in Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) by 66.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 323,397 shares of the company's stock after selling 632,861 shares during the quarter. New York State Common Retirement Fund's holdings in Orchard Therapeutics were worth $230,000 at the end of the most recent reporting period.
根據紐約州共同退休基金提交給美國證券交易委員會的最新文件，該基金在第一季度減持了Orchard Treateutics Plc(納斯達克：ORTX-GET評級)66.2%的股份。該公司在本季度出售了632,861股後，持有323,397股該公司股票。在最近一個報告期結束時，紐約州共同退休基金在Orchard Treeutics持有的股份價值23萬美元。
Separately, SG Americas Securities LLC purchased a new stake in Orchard Therapeutics during the 4th quarter worth about $858,000. Institutional investors and hedge funds own 56.47% of the company's stock.
另外，SG America Securities LLC在第四季度購買了Orchard Treeutics的新股份，價值約85.8萬美元。機構投資者和對衝基金持有該公司56.47%的股票。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, Barclays cut their price target on Orchard Therapeutics from $6.00 to $4.00 in a report on Friday, May 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Orchard Therapeutics has an average rating of "Hold" and a consensus target price of $7.75.
另外，巴克萊在5月13日星期五的一份報告中將Orchard Treeutics的目標價從6.00美元下調至4.00美元。一名投資分析師對該股的評級為賣出，兩名分析師給出了持有評級，三名分析師給出了買入評級。根據MarketBeat的數據，Orchard Treeutics的平均評級為“持有”，共識目標價為7.75美元。
Orchard Therapeutics Price Performance
果園治療藥物性價比
Orchard Therapeutics Company Profile
果園治療公司簡介
(Get Rating)
(獲取評級)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.
Orchard Treateutics公司是一家生物製藥公司，在英國、歐盟和美國開發針對嚴重和危及生命的罕見疾病的基因療法。該公司的基因療法尋求將患者的造血幹細胞轉化為基因修飾的細胞藥物產品，通過單一給藥來治療患者的疾病。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Near-Term Headwinds Present An Opportunity In Ross Stores
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- 免費獲取StockNews.com關於Orchard Treeutics(ORTX)的研究報告
- 2家電動汽車供應商在提出意見後上漲
- 應用材料公司業績顯示半導體市場放緩
- MarketBeat：回顧中的一週8/15-8/19
- 近期逆風為Ross Stores帶來機遇
- 蘋果股價可能再次上漲30%
Want to see what other hedge funds are holding ORTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating).
想看看其他對衝基金持有哪些ORTX嗎？訪問HoldingsChannel.com獲取Orchard Treeutics Plc(納斯達克代碼：ORTX-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《果園治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收Orchard Treeutics和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧